Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia

NACompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2012

Conditions
Opiate Dependence
Interventions
BEHAVIORAL

behavioral drug and HIV risk reduction counseling (BDRC)

BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.

BEHAVIORAL

abstinence-contingent buprenorphine (ACB)

Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.

Trial Locations (2)

84000

Substance Abuse Research Center, Muar town

06519

Yale University School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT00539123 - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia | Biotech Hunter | Biotech Hunter